Biosimilar DMARDs offer cost-effective and improved outcomes over leflunomide for RA patients unresponsive to methotrexate. The study used a Markov model with data from 25,099 RA patients to simulate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback